Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure.
ACLF
acute decompensation
acute-on-chronic liver failure
cirrhosis
natural course
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
30
12
2020
accepted:
22
03
2021
entrez:
29
5
2021
pubmed:
30
5
2021
medline:
19
1
2022
Statut:
ppublish
Résumé
Recently, based on data from the PREDICT study, the European Foundation for the Study of Chronic Liver Failure (EF-CLIF) consortium proposed pathophysiological/prognostic groups in hospitalized patients with cirrhosis: stable decompensated cirrhosis (SDC), unstable decompensated cirrhosis (UDC), pre-acute-on-chronic liver failure (pre-ACLF), and ACLF. We evaluated the outcomes of these subgroups in a real-life cohort of hospitalized patients with cirrhosis. Patients with cirrhosis developing first AD between 09/2010 and 12/2017 at the Vienna General Hospital were evaluated for this retrospective analysis. Two hundred and ten patients with cirrhosis (aged 57.6 ± 11.8 years) including n = 45 (21.4%) SDC, n = 100 (47.6%) UDC, n = 28 (13.3%) pre-ACLF, and n = 37 (17.6%) with ACLF were considered. The proposed AD subgroups discriminated between patients with favorable (1-year mortality: SDC: 6.7% and UDC: 19.6%) and dismal prognosis (90-day mortality: pre-ACLF: 42.9%). Interestingly, systemic inflammation gradually increased (e.g., C-reactive protein, SDC: 0.9 mg/dl, vs. UDC: 2.0 mg/dl vs. pre-ACLF: 3.2 mg/dl, p < 0.001) while renal function was progressively deteriorating (creatinine levels, SDC: 0.8 mg/dl vs. UDC: 0.9 mg/dl vs. pre-ACLF: 1.2 mg/dl, p < 0.001) across prognostic subgroups in patients with cirrhosis. The recently proposed pathophysiological/prognostic EF-CLIF subgroups are also reproduceable in a real-life cohort of cirrhotic patients. As ACLF is a common and important complication, patients at risk of pre-ACLF at index AD should be evaluated and if disease proceeds, been treated early and aggressively to avoid excessive mortality.
Identifiants
pubmed: 34050619
doi: 10.1002/ueg2.12089
pmc: PMC8259248
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
427-437Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.
Références
Liver Transpl. 2020 Jul;26(7):906-915
pubmed: 32365422
J Hepatol. 2020 Oct;73(4):842-854
pubmed: 32673741
Liver Int. 2018 Feb;38 Suppl 1:126-133
pubmed: 29427501
Rev Esp Enferm Dig. 2017 Jun;109(6):399-405
pubmed: 28467096
J Hepatol. 2021 Jan;74(1):200-219
pubmed: 32896580
J Hepatol. 2014 Nov;61(5):1038-47
pubmed: 24950482
Liver Int. 2010 Sep;30(8):1123-30
pubmed: 20536715
Gut. 2020 Nov 16;:
pubmed: 33199442
Eur J Gastroenterol Hepatol. 2018 Feb;30(2):130-135
pubmed: 29200007
World J Gastroenterol. 2019 Oct 21;25(39):5897-5917
pubmed: 31660028
J Hepatol. 2020 Nov;73(5):1082-1091
pubmed: 32339602
J Hepatol. 2015 Apr;62(1 Suppl):S131-43
pubmed: 25920082
Liver Int. 2015 May;35(5):1516-23
pubmed: 24840673
Front Immunol. 2018 Dec 14;9:2948
pubmed: 30619308
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
Gastroenterology. 2019 Jul;157(1):149-162
pubmed: 30905652
Wien Klin Wochenschr. 2012 Jun;124(11-12):395-402
pubmed: 22699260
J Hepatol. 2018 May;68(5):949-958
pubmed: 29331339
Liver Transpl. 2013 Aug;19(8):879-86
pubmed: 23696006
Wien Klin Wochenschr. 2017 Nov;129(Suppl 3):135-158
pubmed: 29063233
Hepatology. 2020 Jul;72(1):230-239
pubmed: 31677284
N Engl J Med. 2020 May 28;382(22):2137-2145
pubmed: 32459924
J Hepatol. 2021 May;74(5):1097-1108
pubmed: 33227350
Liver Int. 2019 Jan;39(1):98-105
pubmed: 30230204
Gastroenterology. 2019 Apr;156(5):1381-1391.e3
pubmed: 30576643
Lancet. 2018 Jun 16;391(10138):2417-2429
pubmed: 29861076
Liver Int. 2015 Sep;35(9):2115-20
pubmed: 25585656
Hepatology. 2015 Jul;62(1):243-52
pubmed: 25877702
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Alcohol Alcohol. 2020 Oct 20;55(6):698-699
pubmed: 32556079
Gut. 2018 Oct;67(10):1870-1880
pubmed: 28847867
Hepatology. 2009 Dec;50(6):2022-33
pubmed: 19885876
PLoS One. 2018 Jan 9;13(1):e0189414
pubmed: 29315304
Dig Liver Dis. 2019 Aug;51(8):1144-1151
pubmed: 30862438
JHEP Rep. 2020 Jun;2(3):100113
pubmed: 32289115
Gut. 2021 Feb;70(2):379-387
pubmed: 32241903
J Hepatol. 2018 Mar;68(3):563-576
pubmed: 29111320
J Hepatol. 2021 Apr;74(4):819-828
pubmed: 33075344
Hepatology. 2005 Mar;41(3):422-33
pubmed: 15723320
Nat Rev Dis Primers. 2016 Jun 09;2:16041
pubmed: 27277335
J Hepatol. 2017 Oct;67(4):708-715
pubmed: 28645736
J Gastroenterol. 2012 May;47(5):561-8
pubmed: 22170417
Liver Int. 2019 Jan;39(1):127-135
pubmed: 30107095
Gastroenterology. 2018 Dec;155(6):1816-1827.e9
pubmed: 30144431
Hepatology. 2016 Jun;63(6):2019-31
pubmed: 26528864
J Vis Exp. 2020 Jun 18;(160):
pubmed: 32628153
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908